These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 2720696

  • 1. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
    Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA.
    Cancer Res; 1989 Jun 15; 49(12):3436-40. PubMed ID: 2720696
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J.
    Cancer Res; 1987 Jan 15; 47(2):617-23. PubMed ID: 3791246
    [Abstract] [Full Text] [Related]

  • 3. Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
    Rowinsky EK, Ettinger DS, McGuire WP, Noe DA, Grochow LB, Donehower RC.
    Cancer Res; 1987 Nov 01; 47(21):5788-95. PubMed ID: 3664482
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW, Fanucchi MP, Declan Walsh T, Baltzer L, Yaldaei S, Stevens YW, Gordon C, Tong W, Rifkind RA, Marks PA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [Abstract] [Full Text] [Related]

  • 5. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
    Ward FT, Kelley JA, Roth JS, Lombardo FA, Weiss RB, Leyland-Jones B, Chun HG.
    Cancer Res; 1991 Apr 01; 51(7):1803-10. PubMed ID: 2004365
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 8. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
    Egorin MJ, Zuhowski EG, Cohen AS, Geelhaar LA, Callery PS, Van Echo DA.
    Cancer Res; 1987 Nov 15; 47(22):6142-6. PubMed ID: 3664514
    [Abstract] [Full Text] [Related]

  • 9. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
    Egorin MJ, Conley BA, Forrest A, Zuhowski EG, Sinibaldi V, Van Echo DA.
    Cancer Res; 1987 Nov 15; 47(22):6104-10. PubMed ID: 2959359
    [Abstract] [Full Text] [Related]

  • 10. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 12. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC, Whitfield LR, Grove WR, Rummel S, Grochow LB, Donehower RC.
    Clin Cancer Res; 2000 Oct 15; 6(10):3885-94. PubMed ID: 11051234
    [Abstract] [Full Text] [Related]

  • 13. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
    Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G.
    Cancer Res; 1991 Feb 15; 51(4):1105-8. PubMed ID: 1705165
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B, Donehower RC.
    Cancer Res; 1991 Nov 01; 51(21):5781-5. PubMed ID: 1933848
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
    Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH.
    Clin Cancer Res; 2001 Jun 01; 7(6):1569-76. PubMed ID: 11410492
    [Abstract] [Full Text] [Related]

  • 18. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG.
    Cancer Res; 1993 Mar 01; 53(5):1032-6. PubMed ID: 8439950
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D.
    Cancer Res; 1994 Feb 01; 54(3):709-17. PubMed ID: 8306332
    [Abstract] [Full Text] [Related]

  • 20. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan JM, Ozols RF, O'Dwyer PJ.
    Cancer Res; 1994 Mar 01; 54(5):1220-6. PubMed ID: 8118810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.